TY - JOUR
T1 - High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma
AU - Lossos, Izidore S.
AU - Hosein, Peter J.
AU - Morgensztern, Daniel
AU - Coleman, Francine
AU - Escalón, Maricer P.
AU - Byrne, Gerald E.
AU - Rosenblatt, Joseph D.
AU - Walker, Gail R.
N1 - Funding Information:
Declaration of interest: One of the authors (I.S.L.) is supported by NIH CA109335, NIH CA122105, Fidelity Foundation, and the Dwoskin Family Foundation.
PY - 2010/3
Y1 - 2010/3
N2 - Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.
AB - Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 1965 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78 (95 CI: 5191). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.
KW - Chemotherapy
KW - Mantle cell lymphoma
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=77249120575&partnerID=8YFLogxK
U2 - 10.3109/10428190903518345
DO - 10.3109/10428190903518345
M3 - Article
C2 - 20038221
AN - SCOPUS:77249120575
SN - 1042-8194
VL - 51
SP - 406
EP - 414
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -